Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
|Videos|April 5, 2022
Dr. Amy Paller discusses long-term safety and efficacy of ixekizumab in kids
Author(s)Miranda Hester
Dr. Paller discusses the findings of the clinical trial examining the long-term effects of ixekizumab for treating psoriasis in children.
Advertisement
Dr. Paller discusses the findings of the clinical trial discussing the long-term effects of ixekizumab for treating psoriasis in children.
Advertisement
Related to this article
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.
Christina Boull, MD, explains how pediatricians can recognize dermatologic conditions in darker skin tones and address pigment changes and treatment gaps.
Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.
In phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Menstrual irregularities in adolescents: When to investigate
2
FDA proposes cadmium action levels for baby food under Closer to Zero
3
Managing infection risks in children on biologic therapies
4
Contemporary Pediatrics week in review: October 19-23, 2026
5